Unmethylated CpG and VEGF-silencing gene (shVEGF) were co-delivered via a hyaluronic acid (HA)-modified HA/PEI/shVEGF/CpG system to trigger in situ tumor vaccine and antiangiogenic effects. The gene discussed is VEGFA; the disease is neoplasm.